Cargando…

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports

INTRODUCTION: Skull base metastasis of prostate cancer associated with cranial nerve palsy is rare. We observed three patients with aggressive prostate cancer who experienced cranial nerve palsy. CASE PRESENTATION: Case 1 was a 53‐year‐old patient who was treated with carboplatin and etoposide. He n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yasumizu, Yota, Kosaka, Takeo, Hongo, Hiroshi, Mizuno, Ryuichi, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924080/ https://www.ncbi.nlm.nih.gov/pubmed/33718819 http://dx.doi.org/10.1002/iju5.12255

Ejemplares similares

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
por: Kosaka, Takeo, et al.
Publicado: (2019)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2021)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
por: Kamisawa, Ken, et al.
Publicado: (2019)

Predictors of urinary function recovery after laparoscopic and robot-assisted radical prostatectomy
por: Hakozaki, Kyohei, et al.
Publicado: (2022)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Editorial Comment from Dr Hamidi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Hamidi, Nurullah
Publicado: (2021)

Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy
por: Matsumoto, Kazuhiro, et al.
Publicado: (2021)

Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy
por: Mizuno, Ryuichi, et al.
Publicado: (2022)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2022)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Editorial Comment from Dr Hirayama and Dr Iguchi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Pulmonary metastasis secondary to abiraterone‐resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case
por: Izawa, Mizuki, et al.
Publicado: (2020)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference
por: Fujita, Kazutoshi, et al.
Publicado: (2022)

Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review
por: Masuda, Tsukasa, et al.
Publicado: (2022)

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion
por: Shojo, Kazunori, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy
por: Hongo, Hiroshi, et al.
Publicado: (2021)

A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

Calvarial-orbital Metastasis of Prostate Carcinoma which was Diagnosed with Sixth Cranial Nerve Palsy
por: Özbek, Zühtü, et al.
Publicado: (2017)

Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3eenrga5euuu2oj4aap2mglkds